GleamWall
中文EN

IBIO iBio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%

Returns

ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$100,000$400,000
R&D expense$19.64M$8.31M
SG&A expense$10.60M$10.69M
Operating income-$35.14M-$18.60M
Interest expense$53,000$212,000
Pretax income-$33.04M-$18.38M
Income tax$0$0
Net income-$33.04M-$18.38M
EBITDA-$34.58M-$18.12M
EPS (basic)-0.32-1.75
EPS (diluted)-0.32-1.75
Weighted avg. shares (diluted)104.06M10.50M
Balance sheet
Cash & equivalents$56.40M$8.79M
Short-term investments$31.64M$0
Receivables—$0
Current assets$92.22M$9.72M
PP&E, net$3.09M$3.16M
Intangibles$1.82M$6.85M
Total assets$99.11M$23.18M
Current liabilities$11.74M$6.11M
Total liabilities$13.40M$8.30M
Shareholders' equity$85.71M$14.88M
Shares outstanding55.70M19.35M
Cash flow statement
Operating cash flow-$23.22M-$15.30M
Capital expenditure$578,000$16,000
Free cash flow-$23.80M-$15.32M
Investing cash flow-$32.00M$742,000
Financing cash flow$103.05M$8.93M
Depreciation & amortization$558,000$484,000
Stock-based compensation$1.37M$1.53M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.